Inhibitors of BCL-2
A purified polypeptide includes an amino acid sequence consisting of about 10 to 80 amino acids, the amino acid sequence having a sequence identity at least 90% homologous to a portion of SEQ ID NO:1. The polypeptide inhibits binding of Bcl-2 to IP 3 receptors of cells that express IP 3 R and Bcl-2 and induces apoptosis in a cell.
1. A method of inducing apoptosis in a cell expressing Bcl-2 and IP 3 R, comprising:
administering to the cell an effective amount of a peptide, the peptide including an amino acid sequence consisting of about 10 to 80 amino acids, the amino acid sequence having a sequence identity at least 90% homologous to about 10 to 80 consecutive amino acids of SEQ ID NO:1, the peptide inhibiting binding of Bcl-2 to IP 3 R of the cell and inducing apoptosis of the cell.
2. The method of claim 1 , the peptide reversing the interaction of Bcl-2 with IP 3 R of cells that express IP 3 R and Bcl-2.
3. The method of claim 1 , the peptide further comprising a second amino acid sequence that facilitates transport of the peptide across a biological membrane.
4. The method of claim 1 , further comprising administering to the cells a second agent that inhibits binding of Bcl-2 to BH3 pro-apoptotic proteins.
5. The method of claim 4 , the second agent comprising at least one of a chromene, a thiazolidine, a benzenesulfonyl, a benzenesulfonamide, an antimycin, a dibenzodiazocine, a terphenyl, an indole, gossypol, apogossypol, an epigallocatechingallate, or a theaflavin.
6. The method of claim 4 , the second agent comprising N-(4-(4-(4′-chloro-biphenyl-2-ylmethyl)-piperazin-1-yl)-benzoyl)-4-(3-dimethylamino-1-phenylsulfanylmethyl-propylamino)-3-nitro-benzenesulfonamide or ABT-737.
7. A method of treating a neoplastic disorder in a subject, comprising:
administering to neoplastic cells of the subject expressing IP 3 R and Bcl-2 a therapeutically effective amount of a peptide, the peptide including an amino acid sequence consisting of about 10 to 80 amino acids, the amino acid sequence having a sequence identity at least 90% homologous to about 10 to 80 consecutive amino acids of SEQ ID NO:1, the peptide inhibiting binding of Bcl-2 to IP 3 R of the cells and inducing apoptosis of the cells, and a therapeutically effective amount of a second agent that inhibits binding of Bcl-2 to BH3 pro-apoptotic proteins of the cells.
8. The method of claim 7 , the amino acid sequence is selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3.
9. The method of claim 7 , the second agent comprising at least one of a chromene, a thiazolidine, a benzenesulfonyl, a benzenesulfonamide, an antimycin, a dibenzodiazocine, a terphenyl, an indole, gossypol, apogossypol, an epigallocatechingallate, or a theaflavin.
10. The method of claim 7 , the second agent comprising N-(4-(4-(4′-chloro-biphenyl-2-ylmethyl)-piperazin-1-yl)-benzoyl)-4-(3-dimethylamino -1-phenylsulfanylmethyl-propylamino)-3-nitro-benzenesulfonamide or ABT-737.
11. A method of inducing apoptosis in a cell expressing Bcl-2 and IP 3 R, comprising:
administering to the cell an effective amount of a peptide, the peptide including an amino acid sequence selected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO: 3, the peptide inhibiting binding of Bcl-2 to IP 3 R of the cell and inducing apoptosis of the cell.
12. The method of claim 11 , the peptide further comprising a second amino acid sequence that facilitates transport of the peptide across a biological membrane.
13. The method of claim 11 , further comprising administering to the cells a second agent that inhibits binding of Bcl-2 to BH3 pro-apoptotic proteins.